Related Experiment Video
Updated: Jan 26, 2026

Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
Published on: February 10, 2023
Crizotinib in Chinese Patients with ROS1-Rearranged Advanced Non‒Small-Cell Lung Cancer in Routine Clinical Practice
Chang Liu1,2, Hui Yu1,2, Jianhua Chang1,2
1Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
Background:
Approximately 1-2% of patients with non‒small-cell lung cancer (NSCLC) harbor ROS1 rearrangements. Crizotinib, an oral small-molecule tyrosine kinase inhibitor (TKI) that targets anaplastic lymphoma kinase (ALK), MET, and ROS1, has shown marked antitumor activity in patients with ROS1-positive advanced NSCLC.
Objective:
Our objective was to analyze the efficacy and safety of crizotinib treatment in Chinese patients with advanced NSCLC with ROS1 rearrangement in real-world clinical practice.
Methods:
We included 35 patients with ROS1-positive NSCLC in this retrospective analysis. All received crizotinib 250 mg twice daily between March 2016 and April 2018 at the Fudan University Shanghai Cancer Center. All had histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangements, which were identified by fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction, or next-generation sequencing. The main outcome measures were progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and adverse events.
Results:
The median age of the patients was 51.0 years; 23 (65.7%) were female and 28 (80.0%) were never smokers. All were diagnosed as having adenocarcinoma; eight patients (22.9%) had brain metastases at baseline. The ORR and DCR were 71.4% and 94.3%, respectively. The estimated median PFS was 11.0 months (95% confidence interval [CI] 7.8-14.2). The estimated median OS was 41.0 months (95% CI 22.5-59.5). Elevated transaminases (54.3%), vision disorder (25.7%), elevated blood creatinine (22.9%), diarrhea (20.0%), and vomiting (20.0%) were the most commonly reported adverse effects.
Conclusion:
Crizotinib was effective and well tolerated in Chinese patients with ROS1-positive advanced NSCLC in real-world clinical practice. The progression sites and patterns, as well as treatments after first disease progression on crizotinib were diverse. Crizotinib beyond progressive disease and local therapy after failure of crizotinib treatment were feasible and effective in clinical practice.
Insights
Crizotinib demonstrated significant efficacy and good tolerability in Chinese patients with ROS1-positive non-small cell lung cancer (NSCLC). This real-world study confirms its effectiveness in managing advanced NSCLC with ROS1 rearrangements.
Area of Science:
- Oncology
- Pharmacology
- Genetics
Background:
- ROS1 rearrangements occur in 1-2% of non-small cell lung cancer (NSCLC) cases.
- Crizotinib is a tyrosine kinase inhibitor (TKI) effective against ALK, MET, and ROS1.
- Previous studies show crizotinib's antitumor activity in ROS1-positive advanced NSCLC.
Purpose of the Study:
- To evaluate the real-world efficacy and safety of crizotinib in Chinese patients with advanced NSCLC and ROS1 rearrangement.
- To analyze progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and adverse events.
Main Methods:
- Retrospective analysis of 35 Chinese patients with ROS1-positive NSCLC treated with crizotinib (250 mg twice daily).
- Patients had histologically or cytologically confirmed locally advanced or metastatic NSCLC with ROS1 rearrangements.
- ROS1 rearrangements were identified using fluorescence in situ hybridization, reverse transcriptase polymerase chain reaction, or next-generation sequencing.
Main Results:
- The objective response rate (ORR) was 71.4% and the disease control rate (DCR) was 94.3%.
- Median progression-free survival (PFS) was 11.0 months, and median overall survival (OS) was 41.0 months.
- Common adverse events included elevated transaminases (54.3%), vision disorder (25.7%), and elevated creatinine (22.9%).
Conclusions:
- Crizotinib is effective and well-tolerated in Chinese patients with ROS1-positive advanced NSCLC in real-world practice.
- Treatment beyond progressive disease and local therapy after crizotinib failure were feasible and effective.
- Diverse progression patterns and subsequent treatments were observed.
More Related Videos
Related Concept Videos
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
[3,3] Sigmatropic Rearrangement of Allyl Vinyl Ethers: Claisen Rearrangement
Preparation of Diols and Pinacol Rearrangement
The reaction begins with transferring a proton from the acid catalyst to one of the hydroxyl groups, producing an oxonium ion.
Lung Capacity
Characteristics of Practical Op Amps
The ratio of differential gain to the common-mode gain is defined as the common-mode rejection ratio (CMRR). This ratio quantifies the ability of operational amplifiers (op-amps) to reject common-mode...
Theoretical Foundations of Nursing Practice
Theories provide a perspective to assess patients' conditions and organize data and methods. They also assist in analyzing and interpreting information. They represent a...

